Investment
Features
FeesSafety
Academy
More
Pluang+

Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs Novavax Inc (NVAX) Price & Performance

State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Novavax Inc — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77, while Novavax Inc trades at $7.94 (market cap $1.30B). The key difference: State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

FLRNNVAX
Sector
Sector/ThematicHealth
52-Week High
$30.86$11.19
52-Week Low
$30.65$6.22
Market Cap
$1.30B
Enterprise Value
$879.40M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF

FLRN trades at $30.76 with minimal daily movement (+0.03%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock lacks key valuation metrics (P/E, P/S, P/B) in current data. Recent dividend payments of $0.11 suggest stable income distribution, but fundamental analysis is limited without updated financial statements.

Outlook remains cautious due to bearish technical signals and incomplete fundamental data. Investment opportunity hinges on upcoming financial disclosures to assess profitability and growth. Primary risks include market volatility and reliance on future earnings reports for valuation clarity. Investors should await Q2 2026 results for deeper insight.

Novavax Inc

Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.

Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.

Returns comparison

Trailing returns across standard periods

About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF

FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.

Read more on FLRN

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX